Literature DB >> 29637555

Nonconvulsive status epilepticus in rats leads to brain pathology.

Una Avdic1,2, Matilda Ahl1,2, Deepti Chugh1,2, Idrish Ali1,2, Karthik Chary3, Alejandra Sierra3, Christine T Ekdahl1,2.   

Abstract

OBJECTIVE: Status epilepticus (SE) is an abnormally prolonged epileptic seizure that if associated with convulsive motor symptoms is potentially life threatening for a patient. However, 20%-40% of patients with SE lack convulsive events and instead present with more subtle semiology such as altered consciousness and less motor activity. Today, there is no general consensus regarding to what extent nonconvulsive SE (NCSE) is harmful to the brain, which adds uncertainty to stringent treatment regimes.
METHODS: Here, we evaluated brain pathology in an experimental rat and mouse model of complex partial NCSE originating in the temporal lobes with Western blot analysis, immunohistochemistry, and ex vivo diffusion tensor imaging (DTI). The NCSE was induced by electrical stimulation with intrahippocampal electrodes and terminated with pentobarbital anesthesia. Video-electroencephalographic recordings were performed throughout the experiment.
RESULTS: DTI of mice 7 weeks post-NCSE showed no robust long-lasting changes in fractional anisotropy within the hippocampal epileptic focus. Instead, we found pathophysiological changes developing over time when measuring protein levels and cell counts in extracted brain tissue. At 6 and 24 hours post-NCSE in rats, few changes were observed within the hippocampus and cortical or subcortical structures in Western blot analyses of key components of the cellular immune response and synaptic protein expression, while neurodegeneration had started. However, 1 week post-NCSE, both excitatory and inhibitory synaptic protein levels were decreased in hippocampus, concomitant with an excessive microglial and astrocytic activation. At 4 weeks, a continuous immune response in the hippocampus was accompanied with neuronal loss. Levels of the excitatory synaptic adhesion molecule N-cadherin were decreased specifically in rats that developed unprovoked spontaneous seizures (epileptogenesis) within 1 month following NCSE, compared to rats only exhibiting acute symptomatic seizures within 1 week post-NCSE. SIGNIFICANCE: These findings provide evidence for a significant brain pathology following NCSE in an experimental rodent model.
© 2018 The Authors. Epilepsia published by Wiley Periodicals, Inc. on behalf of International League Against Epilepsy.

Entities:  

Keywords:  N-cadherin; diffusion tensor imaging; inflammation; nonconvulsive status epilepticus; synaptic proteins

Mesh:

Year:  2018        PMID: 29637555     DOI: 10.1111/epi.14070

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  10 in total

1.  Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus.

Authors:  Jaideep Kapur; Jordan Elm; James M Chamberlain; William Barsan; James Cloyd; Daniel Lowenstein; Shlomo Shinnar; Robin Conwit; Caitlyn Meinzer; Hannah Cock; Nathan Fountain; Jason T Connor; Robert Silbergleit
Journal:  N Engl J Med       Date:  2019-11-28       Impact factor: 91.245

2.  Acute Non-Convulsive Status Epilepticus after Experimental Traumatic Brain Injury in Rats.

Authors:  Pedro Andrade; Ivette Banuelos-Cabrera; Niina Lapinlampi; Tomi Paananen; Robert Ciszek; Xavier Ekolle Ndode-Ekane; Asla Pitkänen
Journal:  J Neurotrauma       Date:  2019-02-25       Impact factor: 5.269

Review 3.  Pharmacotherapy for Nonconvulsive Seizures and Nonconvulsive Status Epilepticus.

Authors:  Pablo Bravo; Aparna Vaddiparti; Lawrence J Hirsch
Journal:  Drugs       Date:  2021-04-08       Impact factor: 9.546

4.  Pitfalls of Commonly Used Ischemic and Dementia Models Due to Early Seizure by Carotid Ligation.

Authors:  Tsukasa Hirano; Takeshi Mikami; Shoto Yamada; Hiroshi Nagahama; Rei Enatsu; Satoshi Ookawa; Yukinori Akiyama; Nobuhiro Mikuni
Journal:  Neurol Med Chir (Tokyo)       Date:  2021-04-01       Impact factor: 1.742

5.  Evaluating the Clinical Impact of Rapid Response Electroencephalography: The DECIDE Multicenter Prospective Observational Clinical Study.

Authors:  Paul M Vespa; DaiWai M Olson; Sayona John; Kyle S Hobbs; Kapil Gururangan; Kun Nie; Masoom J Desai; Matthew Markert; Josef Parvizi; Thomas P Bleck; Lawrence J Hirsch; M Brandon Westover
Journal:  Crit Care Med       Date:  2020-09       Impact factor: 9.296

6.  Automated Long-Term EEG Review: Fast and Precise Analysis in Critical Care Patients.

Authors:  Johannes P Koren; Johannes Herta; Franz Fürbass; Susanne Pirker; Veronika Reiner-Deitemyer; Franz Riederer; Julia Flechsenhar; Manfred Hartmann; Tilmann Kluge; Christoph Baumgartner
Journal:  Front Neurol       Date:  2018-06-19       Impact factor: 4.003

7.  Dexamethasone as Abortive Treatment for Refractory Seizures or Status Epilepticus in the Inpatient Setting.

Authors:  Alexander B Ramos; Roberto A Cruz; Nicole R Villemarette-Pittman; Piotr W Olejniczak; Edward C Mader
Journal:  J Investig Med High Impact Case Rep       Date:  2019 Jan-Dec

8.  Levetiracetam and N-Cadherin Antibody Alleviate Brain Pathology Without Reducing Early Epilepsy Development After Focal Non-convulsive Status Epilepticus in Rats.

Authors:  Una Avdic; Matilda Ahl; My Andersson; Christine T Ekdahl
Journal:  Front Neurol       Date:  2021-02-24       Impact factor: 4.003

9.  G-alpha interacting protein interacting protein, C terminus 1 regulates epileptogenesis by increasing the expression of metabotropic glutamate receptor 7.

Authors:  Yong Liu; You Wang; Juan Yang; Tao Xu; Changhong Tan; Peng Zhang; Qiankun Liu; Yangmei Chen
Journal:  CNS Neurosci Ther       Date:  2021-10-22       Impact factor: 5.243

10.  Co-administration of Anti microRNA-124 and -137 Oligonucleotides Prevents Hippocampal Neural Stem Cell Loss Upon Non-convulsive Seizures.

Authors:  Pascal Bielefeld; Marijn Schouten; Guido M Meijer; Marit J Breuk; Karlijne Geijtenbeek; Sedef Karayel; Alisa Tiaglik; Anna H Vuuregge; Ruth A L Willems; Diede Witkamp; Paul J Lucassen; Juan M Encinas; Carlos P Fitzsimons
Journal:  Front Mol Neurosci       Date:  2019-02-19       Impact factor: 5.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.